06/23/2026
Cross-Species Antibodies for Research & Therapy
Dr. Charles Rice’s monoclonal antibody portfolio offers cross-species reactivity across multiple assays, supporting research in environmental toxicology, inflammation biology, infectious disease, and diagnostics.
A standout antibody, CU-28-24, shows strong SARS-CoV-2 variant neutralization potential, supporting future opportunities in therapeutic and commercial development.
is CURF’s spotlight on Clemson University innovators and their cutting-edge research. Each featured technology is part of CURF’s licensing portfolio and available for commercial development.